🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Egypt / NCT06762821
Recruiting Not applicable

A 24-month Outcomes of Single- Vs Multiple-visit Revascularization

NCT06762821 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2024-12-21
Last updated
2025-01-08

Condition(s) studied

Necrotic Immature Permanent Incisors

Investigational drug(s) / intervention(s)

Single-visit revascularizationMultiple-visit revascularization

Single-visit revascularization: Revascularization protocol will be performed in single visit

Multiple-visit revascularization: Revascularization protocol will be performed in multiple visit

Study summary

The current randomized clinical trial will be conducted to evaluate the 24-month clinical and radiographic outcomes after revascularization of asymptomatic necrotic immature permanent maxillary incisors using single- or multiple-visit protocol.

Eligibility

Sex
ALL
Min age
7 Years
Max age
13 Years
Healthy volunteers
No
Inclusion Criteria: * Compliant healthy patients who had at least one immature maxillary permanent incisor requiring nonsurgical root canal treatment. * Patients presenting with a diagnosis of pulp necrosis with chronic apical periodontitis confirmed by history, clinical, radiographic and operative examination. * Patient without previous endodontic treatment in affected tooth. Exclusion Criteria: * Patients with systemic conditions (medical, developmental or behavioral) that make routine dental treatment difficult. * Patients taking medications that can interfere with healing or hemostasis. * Patients with allergy to local anesthetics * Children who will not comply to recall program. * Teeth with extensive loss of coronal tissue that require restoration with a post * Teeth with internal or external root resorption

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Minia University Dental Hospita Minya Egypt Recruiting

More Minia University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06762821 on ClinicalTrials.gov ↗ ← All trials in Egypt